Atossa Therapeutics, Inc. (BMV:ATOS)
Mexico · Delayed Price · Currency is MXN | Market Cap | 742.78M -63.9% |
| Revenue (ttm) | n/a |
| Net Income | -678.58M |
| EPS | -78.80 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 159 |
| Open | 76.00 |
| Previous Close | 76.00 |
| Day's Range | 76.00 - 76.00 |
| 52-Week Range | 75.00 - 322.50 |
| Beta | n/a |
| RSI | 31.08 |
| Earnings Date | Aug 13, 2026 |
About Atossa Therapeutics
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January ... [Read more]
News
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) research SEATTLE, May 20, 2...
Atossa Therapeutics Transcript: Status update
Adaptive platform trials like I-SPY are accelerating breast cancer drug development, focusing on early endpoints and individualized therapies. Endoxifen demonstrates strong efficacy and tolerability, with ongoing trials exploring its use in combination regimens. Regulatory engagement and personalized prevention strategies are driving faster, more patient-centered progress.
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY Trials SEATTLE, May 14, 2026 /PRNewswire/...
Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year
“During the quarter, we made meaningful progress advancing our (Z)-endoxifen development strategy across both oncology and rare disease indications,” stated Dr. Steven Quay, M.D., Ph.D., Atossa Therap...
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas...
Atossa Therapeutics Quarterly report: Q1 2026
Atossa Therapeutics has published its Q1 2026 quarterly earnings report on May 8, 2026.
Atossa Therapeutics Earnings release: Q1 2026
Atossa Therapeutics released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Atossa Therapeutics’ Endoxifen shows breast cancer risk prevention in trial
Atossa Therapeutics (ATOS) announced the publication of results from the KARISMA Endoxifen trial in the Journal of the National Cancer Institute. The Phase 2 study evaluated daily oral Endoxifen and…
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
Peer-reviewed data support (Z)-endoxifen's (Endoxifen) potential as a differentiated breast cancer risk prevention candidate by marked reduction of mammographic breast density (MBD) Doses of both 1 mg...
Atossa Therapeutics says FDA grants RPD to (Z)-endoxifen to treat MAS
Atossa Therapeutics (ATOS) announced that the U.S. FDA has granted Rare Pediatric Disease designation to (Z)-endoxifen for the treatment of McCune-Albright Syndrome in females. RPD designation is gran...
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
Designation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atossa for a Priority Review Voucher award upon approval SEATTLE, May 4, 2026 /PRNewswire/ -- Atossa Ther...
Atossa Therapeutics Proxy statement: Proxy filing
Atossa Therapeutics filed a proxy statement on March 30, 2026, providing details for shareholder voting and corporate governance matters.
Atossa Therapeutics target adjusted to $25 from $7 at H.C. Wainwright
H.C. Wainwright adjusted the firm’s price target on Atossa Therapeutics (ATOS) to $25 from $7 and keeps a Buy rating on the shares. The firm cites the company’s 1-for-15 reverse…
Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)
2024 EPS was ($3.04). “While we have consistently made meaningful and measurable progress across our (Z)-endoxifen development strategy in oncology over the last 12 months, we continue to explore the…
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other ar...
Atossa Therapeutics Earnings release: Q4 2025
Atossa Therapeutics released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
Atossa Therapeutics Annual report: Q4 2025
Atossa Therapeutics has published its Q4 2025 annual report on March 25, 2026.
Atossa Therapeutics Proxy statement: Proxy filing
Atossa Therapeutics filed a proxy statement on March 20, 2026, providing details for shareholder voting and corporate governance matters.
Atossa Therapeutics announces addition of two biopharma executives to team
Atossa Therapeutics (ATOS) announces the engagement of Kathy Puyana Theall, M.D., as Medical Director – Breast Oncology, and Adebola Giwa, M.D., as Medical Director – Rare Diseases. The addition of…
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
Kathy Puyana Theall, M.D. and Adebola Giwa, M.D.
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
Study Highlights Findings that (Z)-endoxifen Restores Muscle Performance and Lowers Damage Biomarkers in mdx5Cv Dystrophic Mice SEATTLE, March 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasda...
Atossa Therapeutics price target lowered to $10 from $35 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on Atossa Therapeutics (ATOS) to $10 from $35 and keeps a Buy rating on the shares. The firm cites Atossa’s decision to pause Z-endoxifen’s…
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other...
Atossa Therapeutics Slides: Corporate presentation
Atossa Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on February 11, 2026.
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
Atossa's Rare Pediatric Disease Designation for (Z)-endoxifen in neuromuscular diseases qualifies for a future PRV upon FDA approval SEATTLE, Feb. 5, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Na...